{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:25Z","timestamp":1788848425665,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56-AI141494, P51-OD010425, K01-MH123258, 27220140006C"],"award-info":[{"award-number":["R56-AI141494, P51-OD010425, K01-MH123258, 27220140006C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The ongoing COVID-19 vaccine rollout is critical for reducing SARS-CoV-2 infections, hospitalizations, and deaths worldwide. Unfortunately, massive disparities exist in getting vaccines to vulnerable populations, including people living with HIV. Preliminary studies indicate that COVID-19 mRNA vaccines are safe and immunogenic in people living with HIV that are virally suppressed with potent antiretroviral therapy but may be less efficacious in immunocompromised individuals. This raises the concern that COVID-19 vaccines may be less effective in resource poor settings with limited access to antiretroviral therapy. Here, we evaluated the immunogenicity of a single dose COVID-19 replicon RNA vaccine expressing Spike protein (A.1) from SARS-CoV-2 (repRNA-CoV2S) in immunocompromised, SIV infected and immune competent, na\u00efve pigtail macaques. Moderate vaccine-specific cellular Th1 T-cell responses and binding and neutralizing antibodies were induced by repRNA-CoV2S in SIV infected animals and na\u00efve animals. Furthermore, vaccine immunogenicity was elicited even among the animals with the highest SIV viral burden or lowest peripheral CD4 counts prior to immunization. This study provides evidence that a SARS-CoV-2 repRNA vaccine could be employed to induce strong immunity against COVID-19 in HIV infected and other immunocompromised individuals.<\/jats:p>","DOI":"10.3389\/fimmu.2021.800723","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:30:22Z","timestamp":1640046622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques"],"prefix":"10.3389","volume":"12","author":[{"given":"Megan A.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse H.","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieann","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Fredericks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler","family":"Groenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Iwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Wangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah H.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients With Chronic Lymphocytic Leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1111\/ajt.16615","article-title":"Reduced Humoral Response to mRNA SARS-Cov-2 BNT162b2 Vaccine in Kidney Transplant Recipients Without Prior Exposure to the Virus","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and Immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection: A Single-Arm Substudy of a Phase 2\/3 Clinical Trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00099-0","article-title":"Failure to Seroconvert After Two Doses of BNT162b2 SARS-CoV-2 Vaccine in a Patient With Uncontrolled HIV","volume":"8","author":"Touizer","year":"2021","journal-title":"Lancet HIV"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002945","article-title":"Safety and Antibody Response to the First Dose of SARS-CoV-2 Messenger RNA Vaccine in Persons With HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"B6","doi-asserted-by":"publisher","first-page":"ciab648","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With HIV","volume":"22","author":"Woldemeskel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B7","unstructured":"Clinical Features and Prognostic Factors of COVID-19 in People Living With HIV Hospitalized With Suspected or Confirmed SARS-CoV-2 Infection"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/COH.0000000000000654","article-title":"The First 6 Months of HIV-SARS-CoV-2 Coinfection: Outcomes for 6947 Individuals","volume":"16","author":"Johnston","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jama.2019.19775","article-title":"Comorbidities in Persons With HIV: The Lingering Challenge","volume":"323","author":"Lerner","year":"2019","journal-title":"JAMA"},{"key":"B10","unstructured":"Centers for Disease Control and PreventionScience Brief: Evidence Used to Update the List of Underlying Medical Conditions That Increase a Person\u2019s Risk of Severe Illness From COVID-192020"},{"key":"B11","unstructured":"Global HIV & AIDS Statistics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"eabc9396","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-Derived Replicon RNA Vaccine Induces SARS-CoV-2 Neutralizing Antibody and T Cell Responses in Mice and Nonhuman Primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci Transl Med"},{"key":"B13","unstructured":"HDT BioHDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India"},{"key":"B14","unstructured":"HDT BioHDT Bio Partners With Brazil\u2019s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic"},{"key":"B15","unstructured":"HDT BioHDT Bio Announces Agreement With Korea\u2019s Quratis to Co-Develop Innovative COVID-19 Vaccine in Asia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.040","article-title":"Durability of Antibody Responses After Receipt of the Monovalent 2009 Pandemic Influenza A (H1N1) Vaccine Among HIV-Infected and HIV-Uninfected Adults","volume":"29","author":"Crum-Cianflone","year":"2011","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1277844","article-title":"Hepatitis B Virus Vaccination in HIV-Infected People: A Review","volume":"13","author":"Catherine","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ciab438","DOI":"10.1093\/cid\/ciab438","article-title":"The Effectiveness of the TWO-DOSE BNT162b2 Vaccine: Analysis of Real-World Data","volume":"17","author":"Chodick","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ciab687","DOI":"10.1101\/2021.07.08.21259776","article-title":"Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States","volume":"6","author":"Tenforde","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection Against Influenza to mRNA Vaccines But at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1006359","DOI":"10.1371\/journal.ppat.1006359","article-title":"Genetically-Barcoded SIV Facilitates Enumeration of Rebound Variants and Estimation of Reactivation Rates in Nonhuman Primates Following Interruption of Suppressive Antiretroviral Therapy","volume":"13","author":"Fennessey","year":"2017","journal-title":"PloS Pathog"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130188","article-title":"Targeting Antigens to CD180 Rapidly Induces Antigen-Specific IgG, Affinity Maturation, and Immunological Memory","volume":"210","author":"Chaplin","year":"2013","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0253265","DOI":"10.1371\/journal.pone.0253265","article-title":"Effects of Therapeutic Vaccination on the Control of SIV in Rhesus Macaques With Variable Responsiveness to Antiretroviral Drugs","volume":"16","author":"Tunggal","year":"2021","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-6-65","article-title":"Pathogenic Infection of Macaca Nemestrina With a CCR5-Tropic Subtype-C Simian-Human Immunodeficiency Virus","volume":"6","author":"Ho","year":"2009","journal-title":"Retrovirology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1101\/2021.02.15.431215","article-title":"Characterization of Humoral and SARS-CoV-2 Specific T Cell Responses in People Living With HIV","volume":"12","author":"Alrubayyi","year":"2021","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25881","article-title":"Could HIV Infection Alter the Clinical Course of SARS-CoV-2 Infection? When Less Is Better","volume":"92","author":"Mascolo","year":"2020","journal-title":"J Med Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab114","article-title":"Human Immunodeficiency Virus\/AIDS in the Era of Coronavirus Disease 2019: A Juxtaposition of 2 Pandemics","volume":"224","author":"Eisinger","year":"2021","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.626553","article-title":"Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-Human Primates","volume":"12","author":"Shou","year":"2021","journal-title":"Front Microbiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal Models for COVID-19","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.28.458047","article-title":"The Pigtail Macaque (Macaca Nemestrina) Model of COVID-19 Reproduces Diverse Clinical Outcomes and Reveals New and Complex Signatures of Disease","author":"Melton","year":"2021","journal-title":"bioRxiv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1038\/s41467-020-19967-4","article-title":"Cellular Events of Acute, Resolving or Progressive COVID-19 in SARS-CoV-2 Infected non-Human Primates","volume":"11","author":"Fahlberg","year":"2020","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06033-11","article-title":"Dynamics of Simian Immunodeficiency Virus SIVmac239 Infection in Pigtail Macaques","volume":"86","author":"Klatt","year":"2012","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202319","article-title":"Rate of AIDS Progression is Associated With Gastrointestinal Dysfunction in Simian Immunodeficiency Virus-Infected Pigtail Macaques","volume":"190","author":"Canary","year":"2013","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2010.14","article-title":"Compromised Gastrointestinal Integrity in Pigtail Macaques is Associated With Increased Microbial Translocation, Immune Activation, and IL-17 Production in the Absence of SIV Infection","volume":"3","author":"Klatt","year":"2010","journal-title":"Mucosal Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11904-014-0245-5","article-title":"Using the Pathogenic and Nonpathogenic Nonhuman Primate Model for Studying Non-AIDS Comorbidities","volume":"12","author":"Pandrea","year":"2015","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414706","article-title":"Coagulation Biomarkers Predict Disease Progression in SIV-Infected Nonhuman Primates","volume":"120","author":"Pandrea","year":"2012","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.10.016","article-title":"Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys But Not Rhesus Macaques","volume":"191","author":"Blair","year":"2021","journal-title":"Am J Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2104847118","DOI":"10.1073\/pnas.2104847118","article-title":"COVID-19 Cynomolgus Macaque Model Reflecting Human COVID-19 Pathological Conditions","volume":"118","author":"Urano","year":"2021","journal-title":"PNAS"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0150321","DOI":"10.1128\/mBio.01503-21","article-title":"Recovery From Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques","volume":"12","author":"Hasenkrug","year":"2021","journal-title":"mBio"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit937","article-title":"Long-Term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00072-2","article-title":"SARS-CoV-2 Seroprevalence, and IgG Concentration and Pseudovirus Neutralising Antibody Titres After Infection, Compared by HIV Status: A Matched Case-Control Observational Study","volume":"8","author":"Spinelli","year":"2021","journal-title":"Lancet HIV"},{"key":"B45","unstructured":"Centers for Disease Control and PreventionCOVID-19 Vaccination2021"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/evo.14317","article-title":"2020 Hindsight - Should Evolutionary Virologists Have Expected the Unexpected During a Pandemic","volume":"75","author":"Goldhill","year":"2021","journal-title":"Evolution"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.800723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:30:25Z","timestamp":1640046625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.800723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2021.800723"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.800723","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741423998.793592468","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"article-number":"800723"}}